Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George P Kim

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|April 13, 2007
Oxaliplatin in the treatment of colorectal cancerGeorge P Kim, Charles Erlichman
Clinical Colorectal Cancer|December 13, 2005
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathwayGeorge P Kim, Axel Grothey
Biologics : Targets & Therapy|August 27, 2009
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumabGeorge P Kim, Axel Grothey
The Oncologist|February 25, 2025
Select updates from ASCO and ESMO 2024 for gastrointestinal cancer careTim Jang, George P Kim, Thomas J George
Canadian Family Physician Medecin De Famille Canadien|April 16, 2015
Patients with multiple comorbidities: simple teaching strategyW E Osmun, George P Kim, Emily Rae Harrison
Future Oncology (London, England)|October 19, 2020
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinomaGeorge P Kim, Andy Surinach, Frank A Corvino, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2025
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case reportMadeline L Norris, David L DeRemer, Julio D Duarte, et al.
Expert Review of Clinical Pharmacology|March 14, 2017
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOXGeorge P Kim, Monika F Parisi, Manish B Patel, et al.
Investigational New Drugs|May 9, 2015
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium studyKatrina S Pedersen, George P Kim, Nathan R Foster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Predictive value of microsatellite instability-high remains controversialGeorge P Kim, Linda H Colangelo, Soonmyung Paik, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Metabolism & Toxicology|April 13, 2007
Oxaliplatin in the treatment of colorectal cancerGeorge P Kim, Charles Erlichman
Clinical Colorectal Cancer|December 13, 2005
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathwayGeorge P Kim, Axel Grothey
Biologics : Targets & Therapy|August 27, 2009
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumabGeorge P Kim, Axel Grothey
The Oncologist|February 25, 2025
Select updates from ASCO and ESMO 2024 for gastrointestinal cancer careTim Jang, George P Kim, Thomas J George
Canadian Family Physician Medecin De Famille Canadien|April 16, 2015
Patients with multiple comorbidities: simple teaching strategyW E Osmun, George P Kim, Emily Rae Harrison
Future Oncology (London, England)|October 19, 2020
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinomaGeorge P Kim, Andy Surinach, Frank A Corvino, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2025
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case reportMadeline L Norris, David L DeRemer, Julio D Duarte, et al.
Expert Review of Clinical Pharmacology|March 14, 2017
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOXGeorge P Kim, Monika F Parisi, Manish B Patel, et al.
Investigational New Drugs|May 9, 2015
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium studyKatrina S Pedersen, George P Kim, Nathan R Foster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Predictive value of microsatellite instability-high remains controversialGeorge P Kim, Linda H Colangelo, Soonmyung Paik, et al.
Pageof 5